April 10, 2026 4:34pm

Inflation reports warned the consequences of rising energy pricing inflicting wounds in the U.S. economy’s inflation count

CPI was up 3.3% from a year ago, with core prices gaining 2.6% from a year prior.

Geo-political/market update: Iran's ceasefire defiance knots a 3,200 vessels pile-up into the Strait of Hormuz

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

TGIF

 

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

Friday’s RMi Pre-opening: Wavering … https://www.regmedinvestors.com/articles/14378

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

What happened this week and some of the whys with the numbers behind

… it’s NOT always about BUYs/SELLs … it’s about knowing when and what!

 

Friday: The Dow closed DOWN -269.23 points or -0.56%, the S&P closed DOWN -7.77 points or -0.11% while the Nasdaq closed UP +80.477 points or +0.35%

  • Theme of the session: still no end to Iran’s malfeasances

Friday (my) 40-company covered sector’s advance/decline line opened negative with 11 incliners, 27 decliners and 2 flats, ending with a negative close of 7 incliner, 30 decliners and 3 flats

  • Military operation’s pause still presents uncertain outcomes as Iran lies and deceits

Henry’omics: We need to more than consider the economic/political environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • March’s consumer price index report showed that inflation was in line with expectations, at 0.9% for the month and 3.3% on an annual basis. That incorporated a 10.9% jump in energy costs due to the conflict. Excluding energy prices, the report revealed inflation was tame last month. Core CPI increased just 0.2% for the month and 2.6% compared with a year ago, coming in below expectations. Inflation had been sticky at 3% heading into the U.S.-Iran war.
  • University of Michigan survey: A drop in sentiment coincided with a sharp spike in inflation expectations, with respondents seeing prices up 4.8% in a year from now, a full % point rise from the March reading to its highest since August 2025. The one-year outlook in April 2025 was 6.5%.

 

The CBOE Fear (VIX) index, Friday closed at 19.30, after Thursday’s 19.57, Wednesday’s 21.03, Tuesday’s 25.92, Monday’s 24.16 and last Friday was a market holiday

Metrics: Friday …

  • The RUT was down -5.72 points or -0.22%,
  • The XLV was down -2.02 points or -1.35%,
  • The NBI was down -96.79 points or -1.63%;
  • The XBI was down -2.32 points or -1.76%
  • The IWM was down -0.63 or -0.24%;
  • The IBB was down -2.79 points or -1.62%,
  • The VIX was down -0.19points or -0.97% at to 19.30

 

Q2/26 – 1 holiday, 1 neutral, 2 negative and 3 positive closes

  • Q1 -March – 9 positive and 13 negative closes
  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

 

Friday Closing UP (7 of 7)

  • BioNTech (BNTX +$3.52 after Thursday’s -$0.105 after Wednesday’s +$2.46 after Tuesday’s -$1.66 after Monday’s +$0.10),
  • Beam Therapeutics (BEAM +$1.10 after Thursday’s +$0.89 after Wednesday’s +$0.95 after Tuesday’s +$0.26 after Monday’s -$0.43),
  • Alnylam Pharmaceuticals (ALNY +$0.83 after Thursday’s -$2.97 after Wednesday’s +$7.73 after Tuesday’s -$10.82 after Monday’s +$11.49),
  • Mesoblast (MESO +$0.45 after Thursday’s +$0.63),
  • Vericel (VCEL +$0.11 after Thursday’s -$0.44),
  • Cellectis SA (CLLS +$0.09 after Thursday’s -$0.05),
  • Wave Life Sciences (WVE +$0.02),

Flat (3)

  • Brainstorm Cell Therapeutics (BCLI),
  • Generation Bio (GBIO) – acquired
  • Harvard Apparatus TR (OTCQB: HRGN),

Friday’s Closing DOWN (10 of 30):

  • Vertex (VRTX -$10.47 after Thursday’s +$2.82 after Wednesday’s +$12.06 after Tuesday’s -$2.44 after Monday’s -$4.41),
  • IQVA Holdings (IQV -$1.66 after Thursday’s -$3.53 after Wednesday’s +$2.08),
  • Ionis Pharmaceuticals (IONS -$1.26 after Thursday’s +$1.45 after Wednesday’s +$1.09 after Tuesday’s -$0.44 after Monday’s -$0.46),
  • Arrowhead Pharmaceuticals (ARWR -$1.09 after Thursday’s +$1.87 after Wednesday’s +$3.18),
  • AxoGen (AXGN -$1.06 after Thursday’s -$0.98 after Wednesday’s +$3.01 after Tuesday’s -$1.65 after Monday’s -$1.80),
  • Sarepta Therapeutics (SRPT -$1.05 after Thursday’s +$0.33 after Wednesday’s -$1.18 after Tuesday’s +$0.28 after Monday’s -$0.43),
  • uniQure NV (QURE -$0.92 after Thursday’s +$0.41 after Wednesday’s -$1.25 after Tuesday’s -$0.25 after Monday’s +$0.23),
  • Supernus Therapeutics (SUPN -$0.82 after Thursday’s +$0.11),
  • BioLife Solutions (BLFS -$0.74 after Thursday’s +$0.77),
  • Dyne Therapeutics (DYN -$0.68 after Thursday’s +$0.98),

 

The Bottom Line: More of the … WHY and a lot of what ifs …

  • Risk abounds as funds retreat from the cell and gene therapy sector as usual smashed again by econs.

indexes were mixed Friday afternoon following cooler-than-expected inflation data and awaiting any REAL updates about the U.S.-Iran conflict.

As the CPI was “cooler” than expected … while consumer confidence dived!

  • Consumer confidence plunged to a record low in April as fears mounted over rising energy prices and the broader impact of the Iran war, according to a University of Michigan survey.
  • The drop in sentiment coincided with a sharp spike in inflation expectations, with respondents seeing prices up 4.8% in a year from now, a full percentage point rise from the March reading.

Just glad the week is over …

 

April – 2nd week

  • 4/10 - Friday closed negative with 7 incliners, 30 decliners and 3 flats
  • 4/9 - Thursday closed positive with 24 incliners, 13 decliners and 3 flats
  • 4/8 – Wednesday closed positive with 27 incliners, 8 decliners and 5 flats
  • 4/7 – Tuesday closed negative with 15 incliners, 21 decliners and 4 flats
  • 4/6 - Monday closed positive with 20 incliners, 18 decliners and 2 flats

April – 1st week

  • 4/2 - Thursday closed neutral with 19 incliners, 19 decliners and 2 flats
  • 4/1 – Wednesday closed positive with 29 incliners, 8 decliners and 3 flats

March – 5th week

  • 3/31 – Tuesday closed positive with 36 incliners, 2 decliners and 2 flats
  • 3/30 - Monday closed negative with 12 incliners, 26 decliners and 2 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there – closed end funds” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Friday: BioNTech (BNTX), Alnylam Pharmaceuticals (ALNY) and Beam Therapeutics (BEAM)
  • Thursday: Vertex (VRTX), Arrowhead Pharmaceuticals (ARWR) and Ionis Pharmaceuticals (IONS)
  • Wednesday: Vertex (VRTX), Alnylam Pharmaceuticals (ALNY) and Arrowhead Pharmaceuticals (ARWR)
  • Tuesday: Moderna (MRNA), CRISPR Therapeutics (CRSP) and Supernus Therapeutics (SUPN)
  • Monday: Alnylam Pharmaceuticals (ALNY), Entrada Therapeutics (TRDA) and Agenus (AGEN)

The worst three (3) in the session: Losers

  • Friday: Vertex (VRTX), IQIA Holdings (IQV) and Ionis Pharmaceuticals (IONS)
  • Thursday: Alnylam Pharmaceuticals (ALNY), IQIA Holdings (IQV) and AxoGen (AXGN)
  • Wednesday: uniQure NV (QURE), Sarepta Therapeutics (SRPT) and Capricor Therapeutics (CAPR)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and BioNTech (BNTX)
  • Monday: IQIA Holdings (IQV), AxoGen (AXGN) and Vertex (VRTX)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.